Ask Warren

Prestige Biologics

334970 · KOSDAQ · ₩334970 · 프레스티지바이오로직스

₩1,158▼ ₩35 (2.93%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Revenue₩5.7B−₩3.2B₩8.9B₩1.2B−₩135M−₩1.1B₩3B₩342M
Cost of sales₩9.3B₩3B₩13B₩2.5B₩5.2B−₩9.3B₩9.8B₩5.1B
Gross profit−₩3.6B−₩6.3B−₩4.5B−₩1.3B−₩5.4B₩8.2B−₩6.8B−₩4.8B
Operating income−₩4.2B−₩6.2B−₩9.7B−₩14B−₩1.9B−₩9.3B−₩13B−₩9.3B
Net income₩438M−₩20B₩4.6B−₩13B−₩5B−₩3.9B−₩14B−₩6.5B
Net income to shareholders₩438M−₩20B₩4.6B−₩13B−₩5B−₩3.9B−₩14B−₩6.5B

Balance sheet

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Total assets₩270B₩278B₩269B₩269B₩289B₩297B₩292B₩335B
Current assets₩41B₩48B₩41B₩41B₩56B₩61B₩62B₩90B
Cash and equivalents₩1.6B₩10B₩563M₩4.8B₩30B₩35B₩16B₩37B
Total liabilities₩135B₩144B₩155B₩147B₩218B₩220B₩151B₩180B
Current liabilities₩102B₩109B₩128B₩117B₩92B₩95B₩113B₩127B
Borrowings₩91B₩91B₩84B₩93B₩173B₩169B₩90B₩105B
Total equity₩135B₩134B₩114B₩122B₩72B₩77B₩141B₩155B
Shareholders' equity₩135B₩134B₩114B₩122B₩72B₩77B₩141B₩155B

Cash flow

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Cash from operations−₩5.6B−₩25B₩6.3B₩6.2B−₩2.1B₩2.4B−₩1.6B−₩7B
Capital spending₩2.5B−₩1.5B₩2.1B₩2B₩4.3B₩2.4B₩686M₩1.1B
Free cash flow−₩8.1B−₩27B₩4.2B₩4.2B−₩6.4B−₩72M−₩2.3B−₩8.1B

Consolidated where available. Amounts in won.

Also known as: Prestige Biologics / 프레스티지바이오로직스 / 334970 / KRX:334970

Source: KRX statistical information